Key facts
- Debut Biotechnology’s last known valuation is $222.0M (Oct 2023).
- It has raised $89.3M across 4 recorded rounds; the latest was Seed Round ($4.0M) in Nov 2021.
- Notable investors include F-Prime Capital, EDBI, GS Futures, Cavallo Ventures, Sandbox Industries — 23 tracked in total.
- Debut Biotechnology has filed 4 Form Ds with the SEC since 2020, most recently Nov 2021 ($4.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Debut Biotechnology
Funding rounds
4 roundsAbout Debut Biotechnology
Developer of a biotechnology platform designed to create climate-positive products. The company offers features such as research and development capabilities focused on sustainable practices, partnerships with organizations to promote ecological balance, and a commitment to creating environmentally friendly alternatives, fostering product performance rooted in science, enabling businesses to reduce their carbon footprint while contributing positively to environmental and social well-being.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 87
- Website
- debutbiotech.com/
- Ownership
- Privately Held (backing)
Debut Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Debut Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Debut Biotechnology in its N-PORT filings yet. We sweep new filings monthly.